Dergiler / European Journal of Rheumatology / 2017 / Cilt: 4 - Sayı: 1

Investigation of joint hypermobility in individuals with hyperbilirubinemia

Sayfa
36–39
Yayın Tarihi
2022-10-18
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The difference between the groups was statistically significant (p

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Objective: Benign joint hypermobility syndrome refers to hypermobile individuals with musculoskeletal symptoms in the absenceof any systemic rheumatic disease; its prevalence is approximately 0.5%.
📊
Temel Bulgular & Veri:In thisstudy, we aimed to evaluate hypermobility in patients with indirect hyperbilirubinemia.Material and Methods: We recruited 120 consecutive patients with indirect hyperbilirubinemia from a tertiary gastroenterology outpatient clinic and examined them for hypermobility.
💡
Sonuç & Katkı:The difference between the groups was statistically significant (p
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Objective: Benign joint hypermobility syndrome refers to hypermobile individuals with musculoskeletal symptoms in the absenceof any systemic rheumatic disease; its prevalence is approximately 0.5%. In animal studies, bilirubin has been shown to reducefibrosis induced by bleomycin. It has been suggested that bilirubin leads to hypermobility that affects the structure or function ofcollagen. In addition, our observation is that hypermobility occurs more often in patients with indirect hyperbilirubinemia. In thisstudy, we aimed to evaluate hypermobility in patients with indirect hyperbilirubinemia.Material and Methods: We recruited 120 consecutive patients with indirect hyperbilirubinemia from a tertiary gastroenterology outpatient clinic and examined them for hypermobility. Hypermobility was evaluated using the Beighton criteria, and other relevant clinicalfindings were recorded. In addition, a group of healthy individuals (n=107) without hyperbilirubinemia were included as controls.Results: The mean ages of the patients and controls were 33.4±12.9 and 36.2±11.2 years, respectively (p=0.09). In total, 100 (83%) patients and 78 (73%) controls were male (p=0.075). The mean indirect bilirubin levels were 1.44±0.66 mg/dL in the patient group and0.37±0.18 mg/dL in the control group. Based on the Beighton score, 23 patients (19.2%) in the patient group and 3 (2.8%) individualsin the control group had joint hypermobility. The difference between the groups was statistically significant (p

🔖

Bu Makaleye Atıf Yap

ÇINAR, M., YILMAZ, S., ÖZTÜRK, K., DİNÇ, A., ÇETİNDAĞLI, İ., ÇAKAR, M. (2022). Investigation of joint hypermobility in individuals with hyperbilirubinemia. European Journal of Rheumatology, Cilt: 4 - Sayı: 1, 36–39. https://ajindex.com/articles/511709

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (16)

  1. Beighton P, Solomon L, Soskolne CL. Articular mobility in an African population. Ann Rheum Dis 1973
  2. [CrossRef] 2. Carter C, Wilkinson J. Persistent joint laxity and congenital dislocation of the hip. J Bone Jt Surg 1964
  3. Kirk JA, Ansell BM, Bywaters EG. The hypermobility syndrome. Musculoskeletal complaints associated with generalized joint hypermobility. Ann Rheum Dis 1967
  4. [CrossRef] 4. Grahame R, Hakim AJ. Joint hypermobility syndrome is highly prevalent in general rheumatology clinics, its occurrence and clinical presentation being gender, age and race-related. Ann Rheum Dis 2006
  5. 65 (Suppl II): 263. 5. Grahame R, Bird HA, Child A. The revised (Brighton 1998) criteria for the diagnosis of benign joint hypermobility syndrome (BJHS). J Rheumatol 2000
  6. AL-Rawi ZS, Al-Rawi ZT. Joint hypermobility in women with genital prolapse. Lancet 1982
  7. [CrossRef] 7. Gazit Y, Nahir AM, Grahame R, Jacob G. Dysautonomia in the joint hypermobility syndrome. Am J Med 2003
  8. [CrossRef] 8. Sacheti A, Szemere J, Bernstein B, Tafas T, Schechter N, Tsipouras P. Chronic pain is a manifestation of the Ehlers-Danlos syndrome. J Pain Symptom Manage 1997
  9. [CrossRef] 9. Grahame R. Pain, distress and joint hyperlaxity. Joint Bone Spine 2000
  10. Fikree A, Aziz Q, Grahame R. Joint hypermobility syndrome. Rheum Dis Clin North Am 2013
  11. [CrossRef] 11. Wang H, Yamaya M, Okinaga S, Jia Y, Kamanaka M, Takahashi H. Bilirubin ameliorates bleomycin-induced pulmonary fibrosis in rats. 2002
  12. Usharani N, Jayakumar GC, Rao JR, Chandrasekaran B, Nair BU. A microscopic evaluation of collagen-bilirubin interactions: In vitro surface phenomenon. J Microsc 2014
  13. [CrossRef] 13. Gelse K, Pöschl E, Aigner T. Collagens--structure, function, and biosynthesis. Adv Drug Deliv Rev 2003
  14. [CrossRef] 14. Phillips CL, Combs SB, Pinnell SR. Effects of ascorbic acid on proliferation and collagen synthesis in relation to the donor age of human dermal fibroblasts. J Invest Dermatol 1994
  15. [CrossRef] 15. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS, Wakefield LM, et al. Transforming growth factor type beta: rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci 1986
  16. [CrossRef] 16. Mauviel A, Heino J, Kähäri V-M, Hartmann DJ, Loyau G, Pujol JP, et al. comparative effects